Alnylam Pharmaceuticals(US:ALNY)2023-05-04 14:46Financial Performance - Alnylam reported a 48% increase in net product revenues in Q1 2023 compared to Q1 2022, reaching $276 million [63] - Total revenues increased by 50% to $319 million in Q1 2023 compared to $213 million in Q1 2022 [63] - The company's cash and investments stood at $2071 million as of March 31, 2023 [63] - Alnylam reiterates its full-year 2023 net product revenue guidance of $1200 million to $1285 million, representing a 34% to 44% growth compared to 2022 [64] Commercial Highlights - Global TTR net product revenue grew by 49% year-over-year [13] - U S TTR QoQ growth of +5% primarily driven by demand growth +7% due to strong AMVUTTRA demand more than offsetting decrease in ONPATTRO demand [14] - ROW QoQ growth +9% primarily due to AMVUTTRA launch demand in Japan & Germany, ONPATTRO demand in markets where AMVUTTRA not yet available, and timing of orders in partner markets [14] - Total Ultra Rare global Q1 2023 net product revenues were $72 million [15] - Ultra Rare YoY % Growth: GIVLAARI 36%, OXLUMO 66%, Total Ultra Rare 45% [16] Pipeline Development - ALN-APP Phase 1 study in Early-Onset Alzheimer's Disease (EOAD) showed that single doses of ALN-APP were well tolerated to date [28] - ALN-APP Phase 1 Study in EOAD – Interim Results showed Robust and Sustained Reduction in sAPP and sAPP in CSF at the Highest Dose Tested [29] - Topline Phase 1 data for ALN-TTRsc04, an investigational RNAi therapeutic for potential treatment of ATTR Amyloidosis, is expected in late 2023 [53] - Zilebesiran demonstrated >90% mean serum AGT reduction for 6 months after single dose of zilebesiran 800mg [56]